Welcome to our dedicated page for Petmed Express SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetMed Express, Inc. (PETS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and related documents filed with the U.S. Securities and Exchange Commission. As a Florida-incorporated public company listed on Nasdaq, PetMed Express uses these filings to report its financial results, governance decisions, internal control assessments, and material corporate events.
PetMed Express’s recent filings highlight several key themes. The company filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, which incorporates restated financial information following an Audit Committee investigation into revenue recognition practices, vendor promotional reimbursements, and internal controls. In related 8-K filings, the company disclosed that certain prior financial statements should no longer be relied upon due to income statement classification errors and that it expects to report material weaknesses in internal control over financial reporting.
Multiple 8-K and Form 12b-25 (NT 10-Q) filings detail delays in filing the company’s Annual Report and Quarterly Reports, along with Nasdaq notices of non-compliance with Listing Rule 5250(c)(1). These documents describe the company’s plans to complete outstanding filings and seek to regain compliance within the timeframes allowed by Nasdaq. Other 8-K filings cover a non-cash impairment charge related to an indefinite-lived intangible asset associated with the PetCareRx trade name, as well as governance and compensation matters such as leadership changes, interim executive employment terms, and change-of-control and severance arrangements.
Investors can also review filings related to PetMed Express’s shareholder rights plan, including an amendment extending the expiration date of the rights, and disclosures about unsolicited, non-binding acquisition proposals referenced in Schedule 13D amendments and company press releases. Stock Titan’s platform surfaces these filings in real time from EDGAR and pairs them with AI-powered summaries that explain the significance of each document. Users can quickly understand the implications of PetMed Express’s 10-K and 10-Q reports, 8-K event disclosures, and any Form 4 insider transaction reports, helping them interpret complex regulatory information more efficiently.
PetMed Express, Inc. reported receiving a Nasdaq notice on August 20, 2025 stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the year ended March 31, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
The company has until September 1, 2025 to submit a plan to regain compliance and, if Nasdaq accepts the plan, may be given up to December 29, 2025 to become current in its filings. The notice does not immediately affect the listing of PetMed’s common stock on Nasdaq.
PetMed states it is working diligently to complete and file the delayed reports as promptly as possible so it can regain compliance with Nasdaq’s listing standards.
PetMed Express insider purchase reported. Silvercape Investments Ltd filed a Form 4 showing it acquired 101,000 shares of PETS at $3.17 on 08/13/2025, increasing its direct beneficial ownership to 2,579,696 shares. The filing lists the reporting relationship as Director, shows transaction code P (purchase), and is signed by Peter Kennedy on 08/14/2025.
PetMed Express reported that on August 11, 2025 its Chief Executive Officer and President, Sandra Campos, and its Chief Financial Officer and Treasurer, Robyn D’Elia, resigned effective immediately. Under separation agreements the Company will continue each officer’s annual base salary for 13 months ($550,000 for Ms. Campos; $425,000 for Ms. D’Elia), reimburse COBRA premiums for 18 months, and accelerate pro‑rata vesting of certain restricted stock units while other equity awards will be forfeited. The Board reduced its size from six to five and appointed Leslie C.G. Campbell as Interim CEO and President and Doug Krulik as Interim Principal Financial Officer (while he continues as Chief Accounting Officer). The filing discloses an ongoing Audit Committee investigation into autoship revenue recognition, a $50 coupon promotion, and the company’s control environment; a press release was furnished as Exhibit 99.1.
PetMed Express, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 because the company's Audit Committee investigation described in a Current Report filed July 1, 2025 remains incomplete.
The company says completion of that investigation is required to finish and file its Annual Report for the fiscal year ended March 31, 2025, which must be filed before the 10-Q. PetMed indicates a significant change in results is anticipated but cannot reasonably estimate amounts at this time. Contact: Robert Lawsky, General Counsel.
PetMed Express (PETS) Form 4 filing: On 18 Jul 2025, 10% owner Silvercape Investments Ltd purchased 17,565 common shares at $3.23 each (≈$56.7 k). The move raises its directly held stake to 2,360,496 shares. No sales or derivative transactions were disclosed. While the add-on represents only ~0.7% of the owner’s position, continued buying from a >10% holder can signal confidence without materially altering the share count or control position.
PetMed Express Inc. (PETS) Form 4 filing reports that 10% owner Silvercape Investments Ltd purchased 2,817 common shares on 07 July 02 2025 at $3.22 per share, for an outlay of roughly $9.1 thousand. Following the transaction, Silvercape directly holds 2,311,230 shares of PETS. The purchase increases the investor’s stake by about 0.12%, indicating incremental but limited additional commitment to the company.